Low serum deoxyribonuclease I activity is associated with antiTNF-alpha induced skin adverse events in patients with inflammatory bowel disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F12%3A10126648" target="_blank" >RIV/00216208:11320/12:10126648 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.csgh.info/dwnld/gh_2012_1_23_31.pdf" target="_blank" >http://www.csgh.info/dwnld/gh_2012_1_23_31.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Low serum deoxyribonuclease I activity is associated with antiTNF-alpha induced skin adverse events in patients with inflammatory bowel disease

Popis výsledku v původním jazyce

Background: A significant proportion of inflammatory bowel disease (IBD) patients develop skin complications during infliximab or adalimumab therapy. Both drugs are thought to act via induction of apoptosis in activated inflammatory cells. Deoxyribonuclease (DNase) I is endonuclease hydrolyzing double-stranded DNA during apoptosis and its deficiency has been implicated in several autoimmune disorders. Aim: To assess activity of DNase I in patients with IBD and to identify its impact together with otherfactors on development of skin immunopathological complications of biological therapy. Methods: IBD patients treated with infliximab or adalimumab at our centre from 2007-2009 were studied retrospectively for occurrence of skin non-infectious complications during this treatment and assessed for DNase I activity. A random sample of IBD patients treated with biological therapy without skin complications was also assessed. Serum was used to determine DNase I activity by enzyme - linked immu

Název v anglickém jazyce

Low serum deoxyribonuclease I activity is associated with antiTNF-alpha induced skin adverse events in patients with inflammatory bowel disease

Popis výsledku anglicky

Background: A significant proportion of inflammatory bowel disease (IBD) patients develop skin complications during infliximab or adalimumab therapy. Both drugs are thought to act via induction of apoptosis in activated inflammatory cells. Deoxyribonuclease (DNase) I is endonuclease hydrolyzing double-stranded DNA during apoptosis and its deficiency has been implicated in several autoimmune disorders. Aim: To assess activity of DNase I in patients with IBD and to identify its impact together with otherfactors on development of skin immunopathological complications of biological therapy. Methods: IBD patients treated with infliximab or adalimumab at our centre from 2007-2009 were studied retrospectively for occurrence of skin non-infectious complications during this treatment and assessed for DNase I activity. A random sample of IBD patients treated with biological therapy without skin complications was also assessed. Serum was used to determine DNase I activity by enzyme - linked immu

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a slovenská gastroenterologie a hepatologie

ISSN

1213-323X

e-ISSN

—

Svazek periodika

66

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

23-31

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—